• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗血小板因子 4/肝素抗体的结合取决于血小板因子 4 构象变化的热力学。

Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4.

机构信息

ZIK HIKE-Zentrum für Innovationskompetenz, Humorale Immunreaktionen bei Kardiovaskulären Erkrankungen, Greifswald, Germany;

Institut für Immunologie und Transfusionsmedizin, Greifswald, Germany;

出版信息

Blood. 2014 Oct 9;124(15):2442-9. doi: 10.1182/blood-2014-03-559518. Epub 2014 Aug 22.

DOI:10.1182/blood-2014-03-559518
PMID:25150299
Abstract

The chemokine platelet factor 4 (PF4) undergoes conformational changes when complexing with polyanions. This can induce the antibody-mediated adverse drug effect of heparin-induced thrombocytopenia (HIT). Understanding why the endogenous protein PF4 becomes immunogenic when complexing with heparin is important for the development of other negatively charged drugs and may also hint toward more general mechanisms underlying the induction of autoantibodies to other proteins. By circular dichroism spectroscopy, atomic force microscopy, and isothermal titration calorimetry we characterized the interaction of PF4 with unfractionated heparin (UFH), its 16-, 8-, and 6-mer subfractions, low-molecular-weight heparin (LMWH), and the pentasaccharide fondaparinux. To bind anti-PF4/heparin antibodies, PF4/heparin complexes require (1) an increase in PF4 antiparallel β-sheets exceeding ∼30% (achieved by UFH, LMWH, 16-, 8-, 6-mer), (2) formation of multimolecular complexes (UFH, 16-, 8-mer), and (3) energy (needed for a conformational change), which is released by binding of ≥11-mer heparins to PF4, but not by smaller heparins. These findings may help to synthesize safer heparins. Beyond PF4 and HIT, the methods applied in the current study may be relevant to unravel mechanisms making other endogenous proteins more vulnerable to undergo conformational changes with little energy requirement (eg, point mutations and post-translational modifications) and thereby predisposing them to become immunogenic.

摘要

趋化因子血小板因子 4(PF4)与多阴离子结合时会发生构象变化。这可能会引起肝素诱导的血小板减少症(HIT)的抗体介导的药物不良反应。了解为什么 PF4 与肝素结合时会成为自身抗原对于开发其他带负电荷的药物很重要,也可能暗示其他蛋白质自身抗体诱导的更普遍机制。通过圆二色性光谱、原子力显微镜和等温滴定量热法,我们表征了 PF4 与未分级肝素(UFH)、其 16-、8-和 6-mer 亚片段、低分子量肝素(LMWH)和戊多糖磺达肝素的相互作用。为了结合抗 PF4/肝素抗体,PF4/肝素复合物需要(1)增加平行β-sheet 超过约 30%(通过 UFH、LMWH、16-、8-、6-mer 实现),(2)形成多分子复合物(UFH、16-、8-mer),以及(3)能量(构象变化所需),这是由≥11-mer 肝素与 PF4 结合释放的,但较小的肝素不能释放。这些发现可能有助于合成更安全的肝素。除了 PF4 和 HIT 之外,本研究中应用的方法可能与揭示其他内源性蛋白质更容易发生构象变化而不需要少量能量的机制有关(例如,点突变和翻译后修饰),从而使它们更容易成为自身抗原。

相似文献

1
Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4.抗血小板因子 4/肝素抗体的结合取决于血小板因子 4 构象变化的热力学。
Blood. 2014 Oct 9;124(15):2442-9. doi: 10.1182/blood-2014-03-559518. Epub 2014 Aug 22.
2
Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.通过电荷中和使两个血小板因子4四聚体紧密靠近,形成了被肝素诱导的血小板减少症(HIT)抗体识别的抗原。
Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2386-93. doi: 10.1161/01.ATV.0000238350.89477.88. Epub 2006 Jul 27.
3
Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.肝素诱导的血小板减少症:一种基于化学计量学的模型,用于解释普通肝素、低分子量肝素和磺达肝癸钠在不同临床环境中的不同免疫原性。
Thromb Res. 2008;122(2):211-20. doi: 10.1016/j.thromres.2007.11.007. Epub 2008 Feb 8.
4
Characterization of the interaction between platelet factor 4 and homogeneous synthetic low molecular weight heparins.血小板因子4与均一合成低分子量肝素之间相互作用的表征
J Thromb Haemost. 2020 Feb;18(2):390-398. doi: 10.1111/jth.14657. Epub 2019 Oct 20.
5
Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity.多阴离子诱导的血小板因子4构象变化的表征:迈向体外抗原性预测
Thromb Haemost. 2014 Jul 3;112(1):53-64. doi: 10.1160/TH13-08-0634. Epub 2014 Mar 27.
6
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.接受磺达肝癸钠或依诺肝素抗血栓预防的骨科手术患者中的抗血小板因子4/肝素抗体
Blood. 2005 Dec 1;106(12):3791-6. doi: 10.1182/blood-2005-05-1938. Epub 2005 Aug 18.
7
Biophysical tools to assess the interaction of PF4 with polyanions.用于评估 PF4 与聚阴离子相互作用的生物物理工具。
Thromb Haemost. 2016 Oct 28;116(5):783-791. doi: 10.1160/TH16-04-0258. Epub 2016 Sep 22.
8
Polyphosphates form antigenic complexes with platelet factor 4 (PF4) and enhance PF4-binding to bacteria.多聚磷酸盐与血小板因子 4(PF4)形成抗原复合物,并增强 PF4 与细菌的结合。
Thromb Haemost. 2015 Nov 25;114(6):1189-98. doi: 10.1160/TH15-01-0062. Epub 2015 Jul 30.
9
Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds.血小板因子4/肝素键的热力学和动力学性质的定量描述。
Nanoscale. 2015 Jun 14;7(22):10130-9. doi: 10.1039/c5nr02132d. Epub 2015 May 18.
10
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.PF4与肝素的超大复合物是肝素诱导的血小板减少症发病机制的核心。
Blood. 2005 Jan 1;105(1):131-8. doi: 10.1182/blood-2004-04-1544. Epub 2004 Aug 10.

引用本文的文献

1
Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13's conformation.开放还是封闭?了解ADAMTS13构象的分子机制及临床意义。
Hemasphere. 2025 Jul 27;9(7):e70189. doi: 10.1002/hem3.70189. eCollection 2025 Jul.
2
Pleiotropic Effects of Heparin and its Monitoring in the Clinical Practice.肝素的多效性及其在临床实践中的监测。
Semin Thromb Hemost. 2024 Nov;50(8):1153-1162. doi: 10.1055/s-0044-1786990. Epub 2024 May 29.
3
Autoimmune Heparin-Induced Thrombocytopenia.自身免疫性肝素诱导的血小板减少症
J Clin Med. 2023 Nov 3;12(21):6921. doi: 10.3390/jcm12216921.
4
[Research on immunological function of platelet receptor FcγRⅡA].血小板受体FcγRⅡA的免疫功能研究
Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):609-614. doi: 10.3760/cma.j.issn.0253-2727.2023.07.020.
5
When Will Fondaparinux Induce Thrombocytopenia?磺达肝癸钠何时会引起血小板减少症?
Bioconjug Chem. 2022 Aug 17;33(8):1574-1583. doi: 10.1021/acs.bioconjchem.2c00316. Epub 2022 Jul 25.
6
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT).疫苗诱导的免疫性血栓性血小板减少症(VITT)的发病机制。
Semin Hematol. 2022 Apr;59(2):97-107. doi: 10.1053/j.seminhematol.2022.02.004. Epub 2022 Feb 23.
7
Pentosan Polysulfate Inhibits Attachment and Infection by SARS-CoV-2 In Vitro: Insights into Structural Requirements for Binding.戊聚糖多硫酸盐体外抑制 SARS-CoV-2 的附着和感染:结合结构要求的见解。
Thromb Haemost. 2022 Jun;122(6):984-997. doi: 10.1055/a-1807-0168. Epub 2022 Mar 23.
8
Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches.利用组学方法阐明细胞对肝素诱导的血小板减少症的作用。
Front Pharmacol. 2022 Jan 21;12:812830. doi: 10.3389/fphar.2021.812830. eCollection 2021.
9
Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton's Tyrosine Kinase.血液中自发性血小板聚集由 FcγRIIA 刺激布鲁顿酪氨酸激酶介导。
Int J Mol Sci. 2021 Dec 22;23(1):76. doi: 10.3390/ijms23010076.
10
The COVID-19 vaccine ChAdOx1-S is not contaminated with sulfated glycosaminoglycans.新冠病毒疫苗ChAdOx1-S未被硫酸化糖胺聚糖污染。
J Thromb Haemost. 2022 Mar;20(3):777-780. doi: 10.1111/jth.15633. Epub 2022 Jan 14.